Jessica R. Bauman , Geoffrey Liu , Isabel Preeshagul , Stephen V. Liu , Barbara Melosky , Devin Abrahami , Benjamin Li , Despina Thomaidou , Kirsten Duncan , Stan Krulewicz , Martin Rupp , Jessica J. Lin
{"title":"第二代和第三代 ALK 酪氨酸激酶抑制剂治疗 ALK 阳性晚期非小细胞肺癌的真实世界治疗排序和有效性\"[Lung Cancer 195 (2024) 107919]的更正。","authors":"Jessica R. Bauman , Geoffrey Liu , Isabel Preeshagul , Stephen V. Liu , Barbara Melosky , Devin Abrahami , Benjamin Li , Despina Thomaidou , Kirsten Duncan , Stan Krulewicz , Martin Rupp , Jessica J. Lin","doi":"10.1016/j.lungcan.2024.108000","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"197 ","pages":"Article 108000"},"PeriodicalIF":4.5000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Corrigendum to “Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer” [Lung Cancer 195 (2024) 107919]\",\"authors\":\"Jessica R. Bauman , Geoffrey Liu , Isabel Preeshagul , Stephen V. Liu , Barbara Melosky , Devin Abrahami , Benjamin Li , Despina Thomaidou , Kirsten Duncan , Stan Krulewicz , Martin Rupp , Jessica J. Lin\",\"doi\":\"10.1016/j.lungcan.2024.108000\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":18129,\"journal\":{\"name\":\"Lung Cancer\",\"volume\":\"197 \",\"pages\":\"Article 108000\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lung Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0169500224005348\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0169500224005348","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Corrigendum to “Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer” [Lung Cancer 195 (2024) 107919]
期刊介绍:
Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.